For example, human epidermal growth factor receptor 2(HER2) targeted therapies, including trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1), for the treatment of metastatic breast cancer, ovarian cancer and gastric cancer greatly prolonged the survival of HER2-positive patients21–23. Here, ERBB2 is linked to ovarian carcinoma.